Shrinking revenues and increasing costs, YOY: seekingalpha.com
Better products from much larger competitors: seekingalpha.com
EV/EBITDA: -5
EPS: -1
Up 176% for the year
Might be worth targeting a 30% decline in the mid term? Thoughts?
Seeing this falling back down to low 30's. Adding a 10% tranche here at 38.
The fundamentals: XRX wants to buy HPQ, yet XRX is only 30% the size of HPQ. In my opinion, this deal won't go through.
Don't have to be a genius to see that this will have some level of pullback. Although, specifically, I'll target 7 and add to my short if it goes over 12.
I think this stock will recover some of it's losses, regardless of the outcome of the potential FDA restrictions on drug suggestions. The stock has a solid business model and the company has said they are seeing increased demand. This new fields of genetics testing still needs to establish itself in the healthcare payer ecosystem, which presents some risk, but all...
On Fri 09/14, NEPT started putting in higher lows, and we appear to be entering a symmetrical triangle, indicating it has found a bottom. Will monitor through Monday to assess if the bullish trend continues, and if so, will start with a small initial long position.
Looking for a resistance level that causes a reversal of trend. You can see the 2.01 resistance level was hit on 9/6, and 9/7 the price fell through to 1.78. If the downward trend continues, the next resistance level to be hit would be 1.5. Substantial sell volume on 9/5, 9/6 and 9/7 could be indicative of a higher likelihood for a trend reversal early next...
